尤瑞克林治疗急性后循环脑梗死疗效观察

Application of Urinary Kallikrein in Treatment of Acute Ischemic Vertebral Basilar Artery Stroke

【目的】探讨尤瑞克林治疗急性后循环脑梗死的疗效及安全性。【方法】急性后循环脑梗死患者70例，按近、远期时间分为治疗组（n=36）和对照组（n=34）。对照组常规给予抗血小板聚集药物和对症处理，治疗组在对照组治疗的基础上给予尤瑞克林0．15PNAU，静脉滴注，每日1次，连用7天。治疗前后评定患者神经功能缺损（NIHSS）和日常生活活动能力（mRS），并观察临床疗效。检测血尿常规、肝肾功能、凝血功能、心电图，监测血压，观察并记录各种与治．疗相关的不良反应。【结果】与对照组相比，治疗组NIHSS评分和mRS评分显著降低（均P〈O．05），临床疗效显著升高（P〈O．05），不良反应少且轻微。【结论】尤瑞克林治疗急性后循环脑梗死安全、有效，值得临床推广使用。

[Objective] To explore the efficacy and side effects of urinary kallikrein in treating patients with acute ischemic vertebral basilar artery stroke. [Methods]Seventy patients who suffered acute ischemic vertebral basilar artery strokewere divided into trial group（ n = 36） and control group（ n=34） . The control group was given conventional therapy, and the trial group was treated with urinary kallikrein （0.15PNAU/d） for 7 days on the basis of conventional therapy. The neurological deficits and activities of daily living were assessed by Stroke Scale （NIHSS） and Barthel Index （BI） before and after the treatment, respectively. Clinical efficacy was evaluated according to the changes of NIHSS and BI scores. [ResultslCompared with the control group, NIHSS, BI scores and curative effect of the trial group were significantly improved（ P 〈0.05）. [Conclusion]Urinary Kallikrein is effective and safe for the treatment of patients with acute ischemic vertebral basi lar artery stroke, so it is worthy to be recommended for clinical application.